Advertisement

Child Psychiatry & Human Development

, Volume 41, Issue 6, pp 641–648 | Cite as

Buspirone Versus Methylphenidate in the Treatment of Attention Deficit Hyperactivity Disorder: A Double-Blind and Randomized Trial

  • Rozita Davari-Ashtiani
  • Mahin Eslami Shahrbabaki
  • Katayoon Razjouyan
  • Homayoun Amini
  • Homa Mazhabdar
Original Article

Abstract

The efficacy and side effects of buspirone compared with methylphenidate (MPH) in the treatment of children with attention-deficit/hyperactivity disorder (ADHD). A total of 34 children with ADHD as defined by DSM-IV-TR were randomized to buspirone or methylphenidate dosed on weight-adjusted basis at buspirone (0.5 mg/kg/day) and methylphenidate (0.3–1 mg/kg/day) for a 6-week double-blind clinical trial. The principle measures of outcome were the teacher and parent ADHD Rating Scale. The side effects were assessed by the special side effect checklist of each drug. In both groups, the scores of teacher and parent ADHD Rating Scale significantly declined on the 6th week as compared to baseline (p = 0.001). These effects were observed in the subscales too. No significant differences were observed between the two protocols on the total scores of parent and teacher ADHD Rating Scale, but methylphenidate was superior to buspirone in decreasing the symptoms of inattention. The side effects of buspirone were mild and rare in comparison with MPH. Buspirone has a favorable side-effects profile. It also has clinically and statistically significant impacts on improving the ADHD symptoms in children. These preliminary findings of the efficacy of buspirone in children with ADHD need large and cross-over studies.

Keywords

ADHD Buspirone Methylphenidate 

Abbreviations

ADHD

Attention deficit hyperactivity disorder

MPH

Methylphenidate

Notes

Acknowledgments

This work was supported in part by the grant from the Behavioral Sciences Research Center of Shahid Beheshti University of Medical Sciences (Tehran, Iran). The authors express their gratitude to Ali Fakhrabadi and Ebrahim Parvin for editing the manuscript.

References

  1. 1.
    Rowland AS, Lesesne CA, Abramowitz AJ (2002) The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev 8(3):162–170PubMedCrossRefGoogle Scholar
  2. 2.
    Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV et al (2005) Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 57:1442–1451PubMedCrossRefGoogle Scholar
  3. 3.
    Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE et al (1995) Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993–998PubMedGoogle Scholar
  4. 4.
    Raskin LA, Shaywitz BA, Anderson GM, Cohen DJ, Teicher MH, Linakis J (1983) Differential effects of selective dopamine, norepinephrine or catecholamine depletion on activity and learning in the developing rat. Pharmacol Biochem Behav 19:743–749PubMedCrossRefGoogle Scholar
  5. 5.
    Shaywitz BA, Teicher MH, Cohen DJ, Anderson GM, Young JG, Levitt P (1984) Dopaminergic but not noradrenergic mediation of hyperactivity and performance deficits in the developing rat pup. Psychopharmacology (Berl) 82:73–77CrossRefGoogle Scholar
  6. 6.
    Shekim WO, Dekirmenjian H, Chapel JL (1979) Urinary MHPG excretion in minimal brain dysfunction and its modification by d-amphetamine. Am J Psychiatry 136:667–671PubMedGoogle Scholar
  7. 7.
    Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B et al (1997) Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 54:857–864PubMedGoogle Scholar
  8. 8.
    Safer DJ (1997) Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990 s. J Child Adolesc Psychopharmacol 7:267–274PubMedCrossRefGoogle Scholar
  9. 9.
    Wilens TE, Biederman J (1992) The stimulants. Psychiatr Clin North Am 15:191–222PubMedGoogle Scholar
  10. 10.
    Arnold LE (2000) Methyiphenidate vs. amphetamine: comparative review. J Atten Disord 3:200–211CrossRefGoogle Scholar
  11. 11.
    Findling RL, Schwartz MA, Flannery DJ, Manos MJ (1996) Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 57:184–189PubMedGoogle Scholar
  12. 12.
    Klein RG, Landa B, Mattes JA, Klein DF (1988) Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry 45:1127–1130PubMedGoogle Scholar
  13. 13.
    Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM (1993) Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 32:1065–1072PubMedCrossRefGoogle Scholar
  14. 14.
    Kehoe WA (2001) Treatment of attention deficit hyperactivity disorder in children. Ann Pharmacother 35:1130–1134PubMedCrossRefGoogle Scholar
  15. 15.
    Prince JB, Wilens TE, Biederman J, Spencer TJ, Millstein R, Polisner DA et al (2000) A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:193–204PubMedCrossRefGoogle Scholar
  16. 16.
    Temple DL Jr, Yevich JP, New JS (1982) Buspirone: chemical profile of a new class of anxioselective agents. J Clin Psychiatry 43:4–10PubMedGoogle Scholar
  17. 17.
    Taylor D, Hyslop D (1991) Chronic administration of buspirone down-regulates 5-HT2 receptor binding sites. Drug Dev Res 24:93–105CrossRefGoogle Scholar
  18. 18.
    Tunnicliff G, Brokaw JJ, Hausz JA, Matheson GK, White GW (1992) Influence of repeated treatment with buspirone on central 5-hydroxytryptamine and dopamine synthesis. Neuropharmacology 31:991–995PubMedCrossRefGoogle Scholar
  19. 19.
    Castillo C, Ibarra M, Marquez AJ, Villalobos-Molina R, Hong E (1993) Vascular effects of ipsapirone are related with subtypes of alpha 1-adrenergic receptors. Arch Med Res 24:161–168PubMedGoogle Scholar
  20. 20.
    Castillo C, Ibarra M, Marquez JA, Villalobos-Molina R, Hong E (1993) Pharmacological evidence for interactions between 5-HT1A receptor agonists and subtypes of alpha 1-adrenoceptors on rabbit aorta. Eur J Pharmacol 241:141–148PubMedCrossRefGoogle Scholar
  21. 21.
    Sanghera MK, McMillen BA, German DC (1982) Buspirone, a non-benzodiazepine anxiolytic, increases locus coeruleus noradrenergic neuronal activity. Eur J Pharmacol 86:107–110PubMedCrossRefGoogle Scholar
  22. 22.
    Malhotra S, Santosh PJ (1998) An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 37:364–371PubMedCrossRefGoogle Scholar
  23. 23.
    Niederhofer H (2003) An open trial of buspirone in the treatment of attention-deficit disorder. Hum Psychopharmacol 18:489–492PubMedCrossRefGoogle Scholar
  24. 24.
    Neppe V, Young Z (2003) Buspirone as a new treatment for attention deficit disorder and aggression in children and adolescents. Austral J Psychopharmacol 10:47–56Google Scholar
  25. 25.
    Gross MD (1995) Buspirone in ADHD with ODD. J Am Acad Child Adoles Psychiatry 34:1260CrossRefGoogle Scholar
  26. 26.
    DuPaul G (1991) Parent and teacher ratings of ADHD symptoms: psychometric properties in a community-based sample. J Clin Child Psychol 20:245–253CrossRefGoogle Scholar
  27. 27.
    Park E, Cho M, Ki C (2009) Correct use of repeated-measures analysis of variance. Korean J Lab Med 29:1–9PubMedCrossRefGoogle Scholar
  28. 28.
    Neppe V (1990) Innovative psychopharmacotherapy. Raven Press, New YorkGoogle Scholar
  29. 29.
    Neppe V (1999) Cry the beloved mind: a voyage of hope. Brainquest Press DBA Brainvoyage.com, SeattleGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Rozita Davari-Ashtiani
    • 1
    • 2
  • Mahin Eslami Shahrbabaki
    • 1
  • Katayoon Razjouyan
    • 1
  • Homayoun Amini
    • 3
    • 4
  • Homa Mazhabdar
    • 1
  1. 1.Imam Hossein Hospital, Department of PsychiatryShahid Beheshti University of Medical SciencesTehranIran
  2. 2.Behavioral Sciences Research CenterShahid Beheshti University of Medical SciencesTehranIran
  3. 3.Psychiatry and Psychology Research CenterTehran University of Medical SciencesTehranIran
  4. 4.Roozbeh Hospital, Department of PsychiatryTehran University of Medical SciencesTehranIran

Personalised recommendations